Pharmacyte Biotech Inc (OTCMKTS:PMCB) Progresses With Patients Enrollment Process In Pancreatic Cancer Clinical Trial

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is successfully making progress with its enrollments process in a pivotal clinic trial targeting advanced, inoperable pancreatic cancer. It started with the enrollment after the FDA approved its pre-IND request meeting. A host of oncologists, clinicians and renowned scientists will discuss with the U.S. regulatory agency on the related study and gain valuable insight on Investigational New Drug application. This is a step that comes after the enrollment process step in a clinical study.

What is the progress?

With Pharmacyte Biotech and a team of famous oncologists all set to introduce a clinical trial in the United States as well as Europe, the FDA’s IND step is vital to accomplishing the goal. After the IND procedure runs its course, stockholders need to be prepared for a 6-month hard stop in the reported clinical trial could lead in the way of report to the industry. Believing the past performance recorded in previous Pharmacyte clinical trials, the company is quite close to making a powerful story for people with severe, inoperable pancreatic cancer.

The company’s pancreatic cancer therapy has been awarded the Orphan Drug Designation, so if it can repeat the strong performance of earlier clinical trials, there is a strong chance that it could successfully get the breakthrough therapy status from the FDA.

There are two segments specifically that could drive to this designation, and they are the quality of life and how well Pharmacyte’s treatment can shrink inoperable tumors for making them operable. In earlier studies, the firm’s treatment did enhance the quality of life and presented the capacity to shrink a pancreatic tumor.

Pharmacyte has acknowledged that there is presently an unmet medical requirement in a segment of locally advanced pancreatic cancer. There are patients that no longer get any benefit from taking of the combination of Abraxane® and gemcitabine after almost 4-6 months of treatment.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Recent Stories

SignUp Now For Our Featured Newsletter